Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesPrognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
Endocrine-Related Cancer, 06/04/09
Durante C et al. - In a study to evaluate the long-term outcome and prognostic factors for survival in pts with distant metastases from gastroenteropancreatic well-differentiated endocrine carcinoma (GEP WDEC), this study enables the stratification of metastatic GEP WDEC pts into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and to design and interpret clinical trials.
Methods- Long-term outcome and prognostic factors for survival were evaluated in 118 pts with distant metastases from GEP WDEC.
- Inclusion criteria included pathological review by a single pathologist according to WHO criteria, absence of previous therapy apart from surgery, complete morphological evaluation within 3 mos including somatostatin receptor scintigraphy, and follow-up at Gustave-Roussy Institute until death or study's end.
- Clinical, biological marker, and pathological parameters were analyzed in univariate and multivariate statistical models.
- Survival after the first complete imaging work-up of the metastatic disease was determined using Kaplan–Meier method.
- Survival for 5 yrs after diagnosis of metastatic disease was 54%.
- In multivariate analysis, age, number of liver metastases, tumor slope, and initial surgery were predictive of survival.
- 5-yr survival was 100%, 91%, 62%, and 9% when pts had 0, 1, 2, 3, or more poor prognostic features, respectively.
Today in Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Hemoglobin A1C and diabetes diagnosis: The Rancho Bernardo Study
Diabetes Care, 10/28/09
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Update on oral lichen planus
Expert Review of Dermatology, 10/14/09
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Sponsor
Article Search
Sponsor
Sponsor